40% of IBD patients are non-responsive to mainstay therapy

Inflammatory bowel disease (IBD) is characterized by chronic inflammation mediated by cytokine storm and immune cell infiltration. While the precise cause of IBD remains elusive, it can be associated with abnormal immune function, genetic factors, or exposure to environmental triggers including some pathogens. Prioritizing disease models that reflect the patient’s condition is paramount to better understand the pathophysiology of gut inflammation and develop effective treatments.

Patient-derived organoid-based platforms for IBD research

Organoid technology enables the development of patient-derived models that reflect the physiological composition of the gastrointestinal tract in vivo, including all specialized intestinal cell types. Furthermore, it is possible to add layers of complexity to this core epithelial component by incorporating stromal elements and immune cells.

PDO Monolayer

A physiologically relevant human platform to evaluate epithelial barrier function

Our PDO Monolayers are designed to recapitulate the composition of the intestinal epithelium in vivo, including stem cells as well as all differentiated lineages. Starting from patient intestinal crypt biopsies and thanks to our proprietary organoid technology, we have designed a physiological system that allows you to explore inflammatory response, cytotoxicity, and barrier function, and to investigate the protective effect of your compound on the gut epithelium against cytokine-induced damage.

Work with the experts in gut biology and advance with confidence your preclinical candidate to the clinic.

discover more

PDO Co-Cultures

Recapitulate epithelial microenvironment with our co-cultures including bacteria, fibroblasts, or immune cells

The development of successful therapies for inflammatory diseases requires evaluating a drug’s impact on the epithelium as well as the immune and stromal cells. Additionally, the role of the microbiome in triggering inflammatory responses needs to be considered. Modeling these intricate interactions often compromises scalability, posing a challenge for preclinical drug development. We offer unique organoid co-cultures to facilitate the development of candidates targeting pro-inflammatory fibroblasts and immune cells within the gut epithelial microenvironment. Additionally, we also have established co-cultures with gut microbiome that allow screening for preventive therapies in IBD.

talk to sales

Want to know more?


Modelling inflammation “in a dish”

watch now


Patient-derived organoids as a relevant tool for preclinical IBD research and drug development

download now


Organoid-Derived Epithelial Monolayer: A Clinically Relevant In Vitro Model for Intestinal Barrier Function

view publication


Have any questions?

contact us